AZNCF News and Press, AstraZeneca Plc From 04/17/21

AstraZeneca is a hyper-growth blue chip that expects a return to dividend growth in 2022. With one of the most promising drug pipelines in the industry, it could expand far faster than what it's enjoyed historically. In a world where hyper growth often trades at dangerous valuatio...

BioNTech was the first company with an effective vaccine against COVID-19. The stock gained nearly 800% since the IPO in October 2019, which indicates strong optimism among investors. The company has a promising pipeline of treatments and drugs, but many are in the early clinical ...

Genworth Financial finally terminates its deal with China Oceanwide. Tribune Publishing Company receives a revised, non-binding proposal from Newslight. Leaf Group to be acquired by Graham Holdings Company. For further details see: Merger Arbitrage Mondays - Leaf Group A...

Declining SPAC IPOs could indicate the SPAC bubble may have run its course. Brookfield Asset Management agrees to acquire Brookfield Property Partners after increasing its bid by 10%. Aggregate deal value in a highly competitive M&A space approaches $600 billion in Q1 202...

The vaccine supply debate has distracted attention from strong growth at the company. I see the vaccine arguments as a sideshow. The company should make some money from the vaccines, but more importantly, its core businesses are in strong growth mode. After a pullback in recent mo...

President Biden is contemplating suspending intellectual property rights for COVID-19 vaccines. The sooner we vaccinate the entire world, the closer we get to protecting ourselves against COVID-19 and, potentially, new strains. I value MRNA and NVAX based on 1x expected 2022 reven...

Achilles Therapeutics has filed proposed terms for a $176 million U.S. IPO. The firm is developing treatment candidates for various cancers. ACHL won't have data readout until the second half of 2022 for its Phase 1 safety trials, so the IPO may be more suited to institutional inv...

Germany recently temporarily suspended AZN's COVID-19 vaccine due to potential links to blood clots. Europe's drug regulator concluded AZN's vaccine was safe, yet certain Nordic countries have not agreed to resume use of the vaccine. PFE, MRNA or JNJ could be positioned to provide...

A U.S. trial found that AstraZeneca (OTCMKTS: AZNCF) and the University of Oxford’s coronavirus vaccine was 79% effective in preventing the covid-19 virus. Furthermore the vaccine is 100% effective in combating severe disease and hospitalizations. The results from the Phase...

This ETF has performed well in 2020, despite the kind of devastating impact the COVID-19 pandemic had on emerging-market economies like South Africa or Brazil. We anticipate potentially larger macroeconomic discrepancies between the largest and smallest global economies due to the COV...